# Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

Source: https://onco.cc/trials/nct06440057/  
OnCo record `nct06440057` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ZG006 in neuroendocrine tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.

## Summary

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. is a phase 1/2 interventional study registered as NCT06440057 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 78 participants planned, started 2024-08-29 and due to reach its primary completion in 2026-05. Interventions recorded: ZG006.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06440057
- Phase: 1/2
- Setting: A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
- Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT06440057: https://clinicaltrials.gov/study/NCT06440057

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- drugs: [ZG006](https://onco.cc/drugs/zg006/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06440057.json